HIGHLIGHTS
- who: Hiroki Kadota and collaborators from the Department of Gastroenterology, Hiroshima University Hospital, Hiroshima, Japan have published the article: Anti-Programmed Cell Death-1 Antibody and Dasatinib Combination Therapy Exhibits Efficacy in Metastatic Colorectal Cancer Mouse Models, in the Journal: (JOURNAL) of 10/Oct/2020
- what: The authors investigated the in vivo metastasis suppression effects of the plateletderived growth factor receptor inhibitor which targets cancer-associated fibroblasts (CAFs) in with an anti-programmed cell death-1 (PD-1) The aim of the in_vivo studies was to determine the efficacy of the promising candidate dasatinib as . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.